Biogen | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 38.75B 4.31B 2024-12
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
ALKERMES USD 465.2M 11.5M 2024-12
Amgen USD 23.1B 2.79B 2024-12
Bayer EUR 28.95B 3.9B 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Bristol-Myers Squibb USD 24.07B 296M 2025-03
Eli Lilly USD 30.07B 1.69B 2025-03
Gilead Sciences USD 12B 279M 2024-12
Incyte USD 1.89B 244.96M 2025-03
Merck USD 28.42B 1.17B 2024-12
Moderna USD 1.6B 602M 2025-03
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 43B 216M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Regeneron Pharmaceuticals USD 3.57B 2.13B 2025-03
Sanofi 32.22B 3.06B 2025-03
Sanofi 29.16B 865M 2024-12
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Teva Pharmaceutical Industries USD 12.8B 1B 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
United Therapeutics USD 721.5M 16.6M 2025-03
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Biogen Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.